Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.62 billion and $3.52 per share, ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and weight-loss drugs, Mounjaro and Zepbound.

Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential.

Eli Lilly's robust sales for Mounjaro and Zepbound along with its positive outlook for 2025 also work in its favor. Click ...

Mounjaro, the new weight loss drug, is gaining popularity in India for its rapid results. Patients report better appetite control, blood sugar management, and significant weight loss.

Key takeaways Eli Lilly has filed lawsuits against four telehealth companies—Mochi Health, Fella Health, Willow Health, and ...

Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...